AstraZeneca pays $25M upfront, $80M equity investment into Cellectis for gene and cell therapy pact - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
AstraZeneca is beefing up its cell and gene therapy potential by collaborating with and investing in French biotech Cellectis, starting out with a $25 million upfront payment and an $80 million equity investment. AstraZeneca will pay Cellectis $105 million to…